Mesoblast sees little impact from proposed Valeant/Cephalon deal
04 April 2011
Ian Haydock
Please Login to read the full article.
04 April 2011
Ian Haydock
ian.haydock@informa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- Mesoblast off and running in EU with cardiovascular stem cell trial
- S Korea forges ahead in stem cells as Medipost preps for first allogeneic therapy launch
- Biotie drops Newron after Merck Serono's safinamide bombshell
- Mesoblast gains US FDA OK for Phase III mesenchymal precursor cell study
COMMENT
Other Informa Comment
FEATURES
- Interview: Adimab's Gerngross seeks two sweethearts
- Piramal: regulatory overhaul would help India tackle disease challenges
EVENTS
Today
Continental Zara Hotel, Budapest, Hungary
Today
Radisson Blu Royal Hotel, Dublin
Today
Hotel Sofitel Hamburg Alter Wall
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
